New Scaffold against Estrogen Receptor to Inhibit in Breast Cancer
Versandkostenfrei!
Versandfertig in 6-10 Tagen
27,99 €
inkl. MwSt.
PAYBACK Punkte
14 °P sammeln!
Estrogen receptors (ER) are overexpressed in human breast cancers and associated with differentiated tumors with a more favorable prognosis. Paradoxically, these receptors mediate the mitogenic action of estrogens in human breast cancer cells and the efficacy of antiestrogens in adjuvant therapy of primary tumors. The mode of action of overexpression.Estrogen receptors (ER) protein plays a critical role for causing the breast cancer. The exact mechanism underlying the ER protection against cancer progression to metastasis remains to be investigated. Here in this study we show that Pharmacophor...
Estrogen receptors (ER) are overexpressed in human breast cancers and associated with differentiated tumors with a more favorable prognosis. Paradoxically, these receptors mediate the mitogenic action of estrogens in human breast cancer cells and the efficacy of antiestrogens in adjuvant therapy of primary tumors. The mode of action of overexpression.Estrogen receptors (ER) protein plays a critical role for causing the breast cancer. The exact mechanism underlying the ER protection against cancer progression to metastasis remains to be investigated. Here in this study we show that Pharmacophores of Diethylstilbestrol and other four drugs molecules were designed and screened. The main objective of this study is to design a New scaffold to block the estrogen receptor through 'Molecular Docking approach' by using the In silico tools. Further, Chemical Diversity and ADME screening are also desired which increase our ability to predict and model the most relevant pharmacokinetic and metabolic endpoints, thereby accelerating the drug discovery process.
Andere Kunden interessierten sich für
